Clinical trials · Georgia
Relapsed or Refractory Multiple Myeloma clinical trials in Georgia
We’re tracking 92 recruiting relapsed or refractory multiple myeloma studies with a site in Georgia — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Atlanta, GeorgiaAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Newnan, GeorgiaAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04989803RecruitingPhase 1/Phase 2
Tested two lymphoma cell therapies for relapsed or resistant cancer
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
Atlanta, GeorgiaAges 18 years+ - NCT06796504Recruiting
Nerve stimulation for relapsing-remitting multiple sclerosis
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
Atlanta, GeorgiaAges 22–60 - NCT06768489RecruitingPhase 1
Study of a new drug combination for multiple myeloma
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Atlanta, GeorgiaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Atlanta, GeorgiaAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Atlanta, GeorgiaAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Atlanta, GeorgiaAges 18 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Atlanta, GeorgiaAges 18 years+ - NCT05846880RecruitingEarly Phase 1
Vitamin D3 supplement for people with multiple myeloma
This early-phase study tests whether taking a Vitamin D3 supplement can be safe and helpful for people with symptomatic multiple myeloma. It may help researchers understand how Vitamin D affects the disease and how patients tolerate treatment.
Augusta, GeorgiaAges 18 years+ - NCT06177067RecruitingPhase 1
Study of 3 drugs for young AML patients with genetic changes
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
Atlanta, GeorgiaAges 1–30 - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
Atlanta, GeorgiaAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Atlanta, GeorgiaAges 18 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Newnan, GeorgiaAges 18 years+ - NCT06620302RecruitingPhase 1/Phase 2
Adding DT2216 to chemo for relapsed solid tumors and FLC
This trial is testing whether adding a new drug, DT2216, to standard chemotherapy can help treat solid tumors (not starting in the brain) or fibrolamellar carcinoma (FLC) that have come back or not responded to treatment. It's for children, teens, and young adults (ages 1 to 39).
Atlanta, GeorgiaAges 1–39 - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Atlanta, GeorgiaAges 1–21 - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
Atlanta, GeorgiaAges 1–40 - NCT05828069RecruitingPhase 2
Tovorafenib for young people with worsening Langerhans cell histiocytosis
This Phase 2 trial tests tovorafenib (DAY101) to treat children and young people whose Langerhans cell histiocytosis (LCH) is getting worse, came back, or did not respond to prior treatment. It may help by targeting certain gene changes found in the LCH.
Atlanta, GeorgiaAges 6 months–22 years - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06919900Recruiting
Learning fall-resistant skills in multiple sclerosis
This trial tests if practicing slips and trips can help people with multiple sclerosis learn to prevent falls. You will be exposed to controlled slips and trips to improve your balance and walking safety.
Atlanta, GeorgiaAges 45–89 - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Atlanta, GeorgiaAges 18 years+
Relapsed or Refractory Multiple Myeloma trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Emory University · 8 studies
- Children's Healthcare of Atlanta · 6 studies
- Georgia State University · 2 studies
- Research Site · 2 studies
- Augusta University Medical Center
- Cancer Treatment Centers of America at Southeastern Regional Medical Center
- City of Hope - Atlanta
- Memorial Health University Medical Center
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed or Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials in Georgia?
- Yes. We're currently tracking 92 recruiting relapsed or refractory multiple myeloma studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.